GlassScriptPhysician profile
Deborah Camiscoli
NPI 1255304663
$744.93
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $458 · 2021: $160.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $194.16 | 2019-2020 | |
| Daiichi Sankyo INC. | $84.44 | 2020-2021 | |
| Amarin Pharma, INC. | $81.44 | 2019-2021 | |
| Abbvie INC. | $71.32 | 2020-2021 | |
| Genentech USA, INC. | $70.72 | 2019-2021 | |
| Glaxosmithkline, LLC. | $67.78 | 2019-2021 | |
| Pfizer INC. | $40.18 | 2020 | |
| Medtronic Vascular, INC. | $32.75 | 2020 | |
| Horizon Therapeutics Plc | $23.50 | 2020 | |
| Nevro Corp. | $21.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.99 | 2021 | |
| Lilly USA, LLC | $14.87 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.87 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Camiscoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.